4568 On Other Exchanges
Symbol
Exchange
4568 is not on other exchanges.

daiichi sankyo co ltd (4568) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
--
EPS TTM
--
Shares Outstanding
--
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for DAIICHI SANKYO CO LTD (4568)

Related News

No related news articles were found.

daiichi sankyo co ltd (4568) Related Businessweek News

No Related Businessweek News Found

daiichi sankyo co ltd (4568) Details

Daiichi Sankyo Company, Limited engages in the research, development, manufacture, import, and marketing of pharmaceutical products worldwide. The company’s generic pharmaceuticals include olmesartan, azelnidipine, and amlodipine antihypertensive agents; loxoprofen, an anti-inflammatory analgesic; levofloxacin, a synthetic antibacterial agent; esomeprazole for ulcer treatment; memantine and donepezil for treating alzheimer’s disease; pravastatin and atorvastatin antihyperlipidemic agents; carvedilol for treating hypertension, angina pectoris, and chronic heart failure; iohexol to enhance visibility of diagnostic X-ray imaging; silodosin for treating dysuria; laninamivir for anti-influenza treatment; edoxaban, an anticoagulant; teneligliptin and pioglitazone type 2 diabetes mellitus inhibitors; denosumab for treating bone complications; denosumab for treating osteoporosis; and prasugrel, an antiplatelet agent. Its products also comprise colesevelam for treating hypercholesterolemia and type 2 diabetes mellitus indication, as well as iron sucrose and ferric carboxymaltose injections for treating anemia. The company also provides over the counter products, such as Lulu, combination cold remedy; Daiichi Sankyo Ichoyaku, a multi-ingredient digestive remedy; Loxonin S, an antipyretic analgesic; Patecs, an antiphlogistic analgesic for external use; and Transino for treating melisma. In addition, it offers ActHIB, a haemophilus influenzae type b vaccine; Rotarix, a rotavirus vaccine; Influenza HA Vaccine; and Live Attenuated Measles/Rubella Combined Vaccine. Further, the company manufactures and sells cosmetics, medical equipment, food products, drinking water, active pharmaceutical ingredients, intermediates, and pharmaceuticals and drugs for animals. It has collaboration agreements with AgonOx, Inc.; Dana-Farber Cancer Institute; National Cancer Center of Japan; and Medicines for Malari Venture. The company was founded in 1899 and is headquartered in Tokyo, Japan.

15,249 Employees
Last Reported Date: 06/20/16
Founded in 1899

daiichi sankyo co ltd (4568) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: ¥140.0M
Compensation as of Fiscal Year 2016.
daiichi sankyo co ltd
Daiichi Sankyo Company, Limited Initiates ELIMINATE-AF Study Investigating Once-Daily Lixiana (edoxaban) in Patients Undergoing Catheter Ablation of Non-valvular Atrial Fibrillation

Daiichi Sankyo Company, Limited announced that the first patient has been enrolled into the ELIMINATE-AF study. The multinational, randomized phase 3b study will explore the safety and efficacy of the company's oral, once-daily direct factor Xa-inhibitor edoxaban (known by the brand name LIXIANA outside the US and SAVAYSA in the US) against a vitamin K antagonist in patients with atrial fibrillation (AF) undergoing catheter ablation. The study will investigate the incidence of the composite of all-cause death, stroke and major bleeding (International Society on Thrombosis and Hemostasis [ISTH] definition). Approximately 560 patients will be enrolled in ELIMINATE-AF from 75 clinical sites across Europe, Canada and Asia. In this study, edoxaban will be used with the approved dosage regimen for stroke prevention in atrial fibrillation.

Daiichi Sankyo Announces Collaborative Research on Drugs for Neglected Tropical Diseases

Daiichi Sankyo Company, Limited announced that it has entered into a new joint research agreement with the Drugs for Neglected Diseases initiative (DNDi) with regard to a new research program, the Hit-to-Lead Project, with the aim of developing drug treatments for two neglected tropical diseases (NTDs), leishmaniasis and Chagas disease. In February 2016, Daiichi Sankyo and DNDi launched a High-Throughput Screening (HTS) project of 40,000 compounds from Daiichi Sankyo with the goal of discovering anti-leishmaniasis and anti-Chagas disease compounds, and subsequently identified three compound series. Based on these results, Daiichi Sankyo has signed this agreement to advance a Hit-to-Lead Project to develop derivatives from these three compound series as new leishmaniasis and Chagas disease treatments from April 2017. This collaborative project is funded through the Global Health Innovative Technology Fund (GHIT Fund) Hit-to-Lead Platform (HTLP) and will receive approximately USD 780,000 over a period of 18 months. By developing and producing pharmaceutical agents and improving access to healthcare in developing countries, Daiichi Sankyo is actively contributing towards the third Sustainable Development Goal (SDG) set by the United Nations: ensuring healthy lives and promoting well-being for all people at all ages. Daiichi Sankyo is also contributing to the health and quality of life of people across the globe by participating in this collaborative research project into drugs for NTDs.

Daiichi Sankyo Company, Limited Submits a Supplemental New Drug Application to Japan's Ministry of Health, Labour and Welfare for Additional Indication and Dosage for Ovisot Intracoronary Injection 0.1g in Diagnosis of Vasospastic Angina

Daiichi Sankyo Company, Limited announced that it has submitted a supplemental new drug application to Japan's Ministry of Health, Labour and Welfare for an additional indication and dosage for Ovisot intracoronary injection 0.1g (acetylcholine chloride) for induction of coronary spasm in spasm provocation testing during angiography. The current indication of Ovisot for injection 0.1g (acetylcholine chloride) is for postanesthetic paresis of intestine, acute gastric dilatation with the depressed function of the digestive tract and alopecia areata. The MHLW officially requested that Daiichi Sankyo develop Ovisot intracoronary injection following discussions held February 3, 2016, by the Review Committee for Unapproved or Off-label Use of Drugs with High Medical Needs.

 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

4568 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4568.
View Industry Companies
 

Industry Analysis

4568

Industry Average

Valuation 4568 Industry Range
Price/Earnings 29.3x
Price/Sales 1.8x
Price/Book 1.4x
Price/Cash Flow 30.6x
TEV/Sales 1.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact DAIICHI SANKYO CO LTD, please visit www.daiichisankyo.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.